Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The complement alternative pathway (AP) has been implicated in the pathogenesis of IgA nephropathy (IgAN) and increased activity of Factor B (FB), a key mediator of the AP, is associated with poorer kidney outcomes. Mesangial deposition of IgA and complement, including AP proteins, is often observed in the diagnostic biopsy but there is limited understanding of in situ changes during disease progression or treatment. Sefaxersen (RO7434656, IONIS-FB-LRx), an antisense oligonucleotide (ASO) against FB, is the first AP mRNA-targeting therapy in late-stage development for the treatment of IgAN6. We previously reported reductions in AP activity and urine protein to creatinine ratio (UPCR) in a Phase 2 IgAN study of sefaxersen (NCT04014335)7.
IMAgINATION (NCT05797610) is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of sefaxersen in adults with biopsy-confirmed primary IgAN. The primary endpoint is a change from baseline in 24h UPCR at Week 37. Key secondary endpoints include eGFR slope from baseline at Week 105, time to the composite kidney failure endpoint and patient-reported outcomes. In addition to blood and urine biomarkers, optional kidney biopsy samples will be collected at baseline, Week 37, and Week 105 for histopathology assessments including MEST-C score, complement and immune complex deposition, and exploratory biomarkers of inflammation and fibrosis.
Characterization of baseline and post-treatment kidney tissue biomarkers and their concordance with blood/urine biomarkers and disease progression are expected upon study completion.
The assessment of blood, urine and tissue pathophysiology biomarkers in the placebo-controlled IMAgINATION study of sefaxersen may uniquely support the understanding of systemic and in situ drug mechanism of action, disease modification, and association with disease progression in patients with IgAN.
This abstract was also submitted for the ASN Kidney Week 2025 congress. By submitting the abstract to WCN 2026, abstract authors declare that re-submitting the abstract is permitted by the organizers of the previous congress.
